Courtney Flaherty

The FDA granted LSTA1 rare pediatric disease designation for the treatment of osteosarcoma.

First-line treatment with osimertinib and chemotherapy significantly improved survival outcomes after disease progression in EGFR-mutated NSCLC.

Patients with advanced hepatocellular carcinoma treated with nivolumab plus ipilimumab had an improvement in overall survival compared with standard-of-care TKIs.

A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.

The FDA granted an orphan drug designation to soquelitinib for potential use in T-cell lymphoma.

Patients with BRCA-, ATM- and CDK12-mutated mCRPC treated with frontline olaparib plus abiraterone acetate experienced delays in disease progression and improved outcomes.

Researchers determined that the phase 3 EVOKE-01 trial failed to meet its primary end point of significantly improved OS with sacituzumab govitecan in patients with pretreated non-small cell lung cancer compared with docetaxel.

A fast track designation has been granted by the FDA to the novel BTK degrader, NX-5948, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.

A survival advantage via treatment with lenvatinib plus pembrolizumab was not seen when compared with docetaxel for advanced-stage non–small cell lung cancer whose disease progressed after previous exposure to a PD-L1 inhibitor and platinum-based chemotherapy.

High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.

Olaparib did not significantly improve overall survival compared with chemotherapy in recurrent, platinum-sensitive ovarian cancer.

An analysis of 3 randomized trials showed that acalabrutinib was associated with approximately half the number of cardiac toxicities than with comparator treatments.

Immuno-oncology regimens were linked with improved long-term survival among patients with hepatocellular carcinoma.

Patients with EGFR-mutated non–small cell lung cancer and MET positivity may derive greater benefit from amivantamab plus lazertinib than patients who are MET-negative.

Glofitamab monotherapy led to a 63.6% overall response rate in heavily pretreated patients with Richter syndrome.

The rate of pathologic complete responses with enfortumab vedotin was 36.4% among patients with muscle-invasive bladder.

Nirogacestat significantly reduced pain scores for patients with desmoid tumors.

A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.

Prospective phase 2 data demonstrated that aumolertinib, followed by salvage stereotactic radiation therapy, elicited responses in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.